Pepscan appoints chief business officer

Michiel Lodder joins the Dutch firm from OctoPlus

Pepscan Therapeutics, a Dutch biotech company focused on protein mimicry for the discovery of therapeutics peptides and antibodies, has appointed Michiel Lodder as chief business officer.

Lodder joins the firm from OctoPlus, where he was senior manager business development, responsible for licensing, partnering, and alliance management activities.

Pepscan has recently established a number of research collaboration and licensing agreements with major pharma and biotech companies, and Lodder’s experience is expected to enable the firm to add to these partnerships.

You may also like

Research & Development

Pepscan Therapeutics signs agreement with Crucell

Partners aim to develop of novel vaccines to combat infectious diseases
Research & Development

Pepscan agrees research collaboration with Tibotec

Will use CLIPS to develop therapeutic peptides
Research & Development

Immunovo secures seed funding from venture capitalists

Signs partnering agreement with Pepscan, which takes minority interest in Immunovo
Manufacturing

Nulogy launches Supplier Compliance Management to build stronger, more resilient supplier networks

Nulogy, a leading provider of manufacturing operations software, announced the launch of Nulogy Supplier Compliance Management, a solution designed to centralise and automate supplier compliance for procurement, supply chain, and quality assurance teams in manufacturing, food & beverage, pharmaceuticals, and other highly regulated industries
Regulatory

The challenges of developing combination products

Regulatory complexity and the case for a holistic development strategy
Ingredients

dsm-firmenich launches ModulaSENSE Bitter to tackle bitterness in oral drug formulations

The new taste modulation technology combines bitter blockers, maskers and sweeteners with receptor-based analysis to help pharmaceutical formulators improve the palatability of oral medicines
You need to be a subscriber to read this article.
Click here to find out more.
Analysis

Semaglutide patent cliff: pharma industry braces for impact

With the weight-loss industry shifting from a monopoly held by innovators to a high-volume, competitive generic market, the pharma manufacturing sector is gearing up for a "generic wave" with investments into large-scale protein synthesis and facilities for injectables
Subscribe now